Item 7.01. Regulation FD Disclosure.

The following information is being furnished under Item 7.01 of Form 8-K: The press release filed by the Company's majority owned subsidiary, Biovest International, Inc. ("Biovest") on June 11, 2008, titled "Biovest Reports Blinded Results for Phase 3 Study Evaluating Anti-Cancer Vaccine, BiovaxID®, which Shows 100% Difference in Disease-Free Survival at 36 Months in the Comparative Arms". A copy the press release filed by Biovest is attached hereto as Exhibit 99.1.

Item 9.01. Financial Statements and Exhibits.

See the Exhibit Index set forth below for a list of exhibits included with this Form 8-K.

---